CSL マネジメント

マネジメント基準チェック /14

CSLの CEO はPaul McKenzieで、 Mar2023年に任命され、の在任期間は 1.67年です。の年間総報酬は$ 8.18Mで、 23.1%給与と76.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.005%を直接所有しており、その価値は€ 4.03M 。経営陣と取締役会の平均在任期間はそれぞれ1.7年と4.9年です。

主要情報

Paul McKenzie

最高経営責任者

US$8.2m

報酬総額

CEO給与比率	23.1%
CEO在任期間	1.7yrs
CEOの所有権	0.005%
経営陣の平均在職期間	1.7yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Recent updates

CEO報酬分析

CSL の収益と比較して、Paul McKenzie の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

報酬と市場: Paulの総報酬 ($USD 8.18M ) は、 German市場 ($USD 4.86M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Paul McKenzie (58 yo)

1.7yrs

在職期間

US$8,183,842

報酬

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul McKenzie	MD, CEO & Executive Director	1.7yrs	US$8.18m	0.0047% € 4.0m
Joy Linton	Interim Executive Vice President of CSL Behring	less than a year	US$3.73m	0.0025% € 2.1m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.3yrs	US$4.07m	0.00044% € 367.8k
John A. Levy	Interim Chief Financial Officer	less than a year	データなし	データなし
Chris Cooper	Head of Investor Relations	no data	データなし	データなし
Gregory Boss	Executive VP of Legal & General Counsel	15.8yrs	US$2.31m	データなし
Roanne Parry	Chief Human Resources Officer	less than a year	データなし	データなし
Andrew Nash	Senior Vice President of Research	no data	データなし	データなし
William Mezzanotte	Executive VP & Head of Research and Development	6.1yrs	US$2.14m	データなし
Mark Hill	Chief Digital Information Officer & Executive VP	4.1yrs	データなし	データなし
Deirdre BeVard	Senior Vice President of Research & Development Strategic Operations	no data	データなし	データなし
Herve Gisserot	Senior VP & GM of Vifor	1.7yrs	データなし	データなし

1.7yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: CSJの経営陣は経験豊富とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul McKenzie	MD, CEO & Executive Director	1.9yrs	US$8.18m	0.0047% € 4.0m
Megan Clark	Independent Non Executive Director	8.8yrs	US$242.44k	0.0011% € 911.2k
Alison Watkins	Independent Non-Executive Director	3.3yrs	US$240.56k	0.00077% € 643.7k
Carolyn Hewson	Independent Non-Executive Director	4.9yrs	US$237.09k	0.00047% € 392.9k
Brian McNamee	Independent Non-Executive Chairman	6.8yrs	US$604.85k	0.026% € 21.9m
Robert Cuthbertson	Non-Independent Non-Executive Director	6.1yrs	US$221.35k	0.015% € 12.2m
Marie McDonald	Independent Non-Executive Director	11.3yrs	US$215.19k	0.00088% € 735.6k
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% € 342.7k
Elaine Sorg	Independent Non-Executive Director	less than a year	データなし	データなし

4.9yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: CSJの取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

CSL マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Now 20% undervalued

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Now 20% undervalued

Now 22% undervalued

Now 20% undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 22% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Now 21% undervalued after recent price drop

Independent Non-Executive Director recently bought €174k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold €4.3m worth of stock

Upcoming dividend of US$1.18 per share

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 23% undervalued

Upcoming dividend of US$1.04 per share

Now 22% undervalued after recent price drop

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold €2.9m worth of stock

MD, CEO & Executive Director recently sold €3.0m worth of stock

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022

マネジメント基準チェック /14